Replies to post #57026 on Ayala Pharmaceuticals Inc (ADXS)

[oakrock]

ADXS has not sold out, but self financing the bulk of cash load. No sellout yet, self financing, more risk, more reward. I think so much positive on science, that when we break through, our reward will come.

Presentation, while a marketing tool is impressive.

https://www.advaxis.com/wp-content/uploads/2018/02/February-2018-Corporate-Presentation-Final.pdf

Painful right now, but I am keeping faith....based on on all the facts we have in hand..

ADXS-PSA Metastatic Prostate Ph1/2 Combination with pembrolizumab Part
A Monotherapy

Completed

Axalimogene
filolisbac
Persistent Recurrent / Metastatic Cervical Cancer (PRmCC) EU

Conditional Approval Filing Completed

Axalimogene 2018
filolisbac
ADVANCE Metastatic Cervical Ph 3 Combination with
nivolumab Trial Initiation

ADXS-NEO Ph 1 Initiation 1H 2018

ADXS-PSA Metastatic Prostate Ph1/2 Combination with pembrolizumab Part 2018
B Monotherapy Combination Therapy Data


Axalimogene 2018
filolisbac
Announce planned IST in Head and Neck

ADXS-HOT 2018
Multiple IND Filings
First in Human – 1 Tumor Type 2018

and of course

Axalimogene
filolisbac
Metastatic Cervical Ph 1/2 Combo with durvalumab
Part 1 Combination Therapy: Dose Escalation, Dose Determination Completed
Part B Expansion Interim Readout 2019